UY32624A - Procedimiento y composición para mejorar la absorción de agentes terapéuticos - Google Patents

Procedimiento y composición para mejorar la absorción de agentes terapéuticos

Info

Publication number
UY32624A
UY32624A UY0001032624A UY32624A UY32624A UY 32624 A UY32624 A UY 32624A UY 0001032624 A UY0001032624 A UY 0001032624A UY 32624 A UY32624 A UY 32624A UY 32624 A UY32624 A UY 32624A
Authority
UY
Uruguay
Prior art keywords
absorption
procedure
composition
improve
therapeutic agents
Prior art date
Application number
UY0001032624A
Other languages
English (en)
Inventor
Eric R First
Ashish B Patel
Schmitz Guido
Stephanie Petaway-Hickson
Tong Julin
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43062708&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY32624(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of UY32624A publication Critical patent/UY32624A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un comprimido con un perfil de disolución mejorado para un ingrediente medicinalmente activo tal como aspirina y procedimientos para fabricar el comprimido. El comprimido comprende una mezcla de cristales de un ingrediente medicinalmente activo y un coadyuvante de disolución tal como carbonato de sodio o calcio que recubre los cristales al molerlos conjuntamente. La mezcla se prensa después para moldear comprimidos que tienen un perfil de disolución mejorado para el ingrediente medicinalmente activo.
UY0001032624A 2009-05-11 2010-05-11 Procedimiento y composición para mejorar la absorción de agentes terapéuticos UY32624A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12/387,977 US11135188B2 (en) 2009-05-11 2009-05-11 Method and composition to improve absorption of therapeutic agents

Publications (1)

Publication Number Publication Date
UY32624A true UY32624A (es) 2010-12-31

Family

ID=43062708

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032624A UY32624A (es) 2009-05-11 2010-05-11 Procedimiento y composición para mejorar la absorción de agentes terapéuticos

Country Status (15)

Country Link
US (1) US11135188B2 (es)
EP (1) EP2429502B1 (es)
AR (1) AR076864A1 (es)
BR (1) BRPI1013509A2 (es)
CA (1) CA2761678A1 (es)
CL (1) CL2011002807A1 (es)
CO (1) CO6460753A2 (es)
EA (1) EA201171399A1 (es)
HU (1) HUE043173T2 (es)
MX (1) MX2011011928A (es)
PL (1) PL2429502T3 (es)
PT (1) PT2429502T (es)
SI (1) SI2429502T1 (es)
UY (1) UY32624A (es)
WO (1) WO2010132095A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents
WO2014122195A1 (en) * 2013-02-06 2014-08-14 Hermes Arzneimittel Gmbh Pharmaceutical compositions incorporating low-dose drugs
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
HUE061928T2 (hu) 2014-06-11 2023-09-28 SpecGx LLC Különbözõ oldódási profillal rendelkezõ porlasztva szárított készítmények és elõállításukhoz szükséges eljárások
JP6371463B2 (ja) 2014-07-17 2018-08-08 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 即時放出性乱用抑止性液体充填剤形
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11197830B2 (en) * 2019-02-27 2021-12-14 Aft Pharmaceuticals Limited Pharmaceutical composition containing acetaminophen and ibuprofen
WO2022103620A1 (en) * 2020-11-13 2022-05-19 Bayer Healthcare Llc Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof
CN118638044A (zh) * 2023-03-13 2024-09-13 南京济群医药科技股份有限公司 一种快速释放的琥珀酸多西拉敏组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB191225486A (en) 1912-11-06 1913-04-24 Herbert Sefton-Jones Manufacture and Production of Improved Pharmaceutical Preparations.
US2293359A (en) 1941-01-08 1942-08-18 Quisling Sverre Acetyl salicylic acid preparation
FI89004C (fi) 1988-02-16 1993-08-10 Pertti J Neuvonen Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat
RU2099058C1 (ru) 1992-06-15 1997-12-20 Институт химии твердого тела и переработки минерального сырья СО РАН Способ получения твердой быстрорастворимой дисперсной системы, содержащей ацетилсалициловую кислоту
US5665388A (en) 1995-11-13 1997-09-09 Health Corporation Method for preparation of an alkaline and aspirin combination compound
WO1999009988A1 (en) 1997-08-27 1999-03-04 Hexal Ag New pharmaceutical compositions of meloxicam with improved solubility and bioavailability
US8231899B2 (en) * 1998-09-10 2012-07-31 Nycomed Danmark Aps Quick release pharmaceutical compositions of drug substances
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
RU2170582C1 (ru) 2000-02-17 2001-07-20 Институт химии твердого тела и механохимии СО РАН Способ получения быстрорастворимой таблетированной формы ацетилсалициловой кислоты
EP1744757A4 (en) 2004-05-04 2009-04-22 Equitech Corp IMPROVED ENHANCED COMPOSITION
US8216610B2 (en) 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
ES2450648T3 (es) * 2004-06-29 2014-03-25 Takeda Pharma A/S Fabricación de composiciones farmacéuticas con liberación rápida de fármacos insolubles en agua y composiciones farmacéuticas obtenidas mediante el procedimiento de la invención
EP2417969A1 (en) * 2004-10-21 2012-02-15 Aptalis Pharmatech, Inc. Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
AU2006317530B2 (en) 2005-11-28 2011-09-01 Imaginot Pty Ltd Oral therapeutic compound delivery system
US11135188B2 (en) 2009-05-11 2021-10-05 Bayer Healthcare Llc Method and composition to improve absorption of therapeutic agents

Also Published As

Publication number Publication date
AR076864A1 (es) 2011-07-13
EP2429502A1 (en) 2012-03-21
EP2429502A4 (en) 2012-10-24
US20100286100A1 (en) 2010-11-11
CL2011002807A1 (es) 2012-06-15
EP2429502B1 (en) 2018-12-26
WO2010132095A1 (en) 2010-11-18
PT2429502T (pt) 2019-03-29
CO6460753A2 (es) 2012-06-15
CA2761678A1 (en) 2010-11-18
US11135188B2 (en) 2021-10-05
WO2010132095A8 (en) 2011-07-07
BRPI1013509A2 (pt) 2016-04-05
PL2429502T3 (pl) 2019-07-31
HUE043173T2 (hu) 2019-08-28
MX2011011928A (es) 2011-12-06
EA201171399A1 (ru) 2012-05-30
SI2429502T1 (sl) 2019-05-31

Similar Documents

Publication Publication Date Title
UY32624A (es) Procedimiento y composición para mejorar la absorción de agentes terapéuticos
CR10349A (es) Tabletas de paracetamol de liberacion rapida
CR11625A (es) Formulacion de capsula
CR11709A (es) Preparacion solida de desintegracion oral
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
BR112012020731A2 (pt) pastilhas gelatinosas suaves com nicotina.
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
PE20150083A1 (es) Formulacion de ibuprofeno inyectable
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX2019008817A (es) Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma.
DOP2012000277A (es) Comprimido de desintegracion por via oral que contiene acarbosa
CY1122387T1 (el) Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων
ES2720869T3 (es) Composiciones farmacéuticas de sevelámero
AR083095A1 (es) Cocristal de aprepitant l-prolina y composicion farmaceutica
NI201200196A (es) Agentes terapéuticos 976
NI201500027A (es) Formulación de comprimidos compuestos de dos fases que comprenden atorvastatina, irbesartan y carbonato de magnesio.
CL2016002655A1 (es) Composición farmacéutica para el tratamiento de alopatías relacionadas con el dolor, usando como agente activo al ketorolaco trometamina y clorhidrato de tramadol
WO2010042600A3 (en) Photo-activatable therapeutic agents and methods of using
AR094203A1 (es) Formulacion farmaceutica en n-[5-[2-(3,5-dimetoxifenil)etil]-2h-pirazol-3-il]-4-[(3r,5s)-3,5-dimetilpiperazin-1-il]benzamida
MX2014013083A (es) Composicion farmaceutica inyectable de dexketoprofeno y tramadol.
IN2014CN04119A (es)
ECSP11011212A (es) Nueva asociación de ingredientes activos que contienen un fármaco antiinflamatorio, no esteroideo y un derivado de colchicósido
AR063530A1 (es) Procedimiento de utilizacion de enoxaparina sodica para la preparacion de un medicamento
GT200700005A (es) Composicion farmaceutica estable de carisoprodol y meloxicam

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181129